Orelabrutinib in combination with rituximab

PreclinicalMonoclonal antibody

TThe First Affiliated Hospital of Xiamen University

Orelabrutinib in combination with rituximab is one of 26 small molecule programs targeting Lymphoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

LymphomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Oncaspar

SServier

Preclinical

15 2

Norvir

AbbVie

Preclinical

1 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 4

Tafasitamab

Incyte

Preclinical

7 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

PEG-Intron

1 10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

N/ARecruiting

Lymphoma

NCT06478472

Clinical

Trials by Indication[1]

Lymphoma1 trial

Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy

Recruiting·TThe First Affiliated Hospital of Xiamen University·N/A·NCT06478472·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Orelabrutinib in combination with rituximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Orelabrutinib in combination with rituximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Orelabrutinib in combination with rituximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Xiamen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: TThe First Affiliated Hospital of Xiamen University

Orelabrutinib in combination with rituximab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News